Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Latest Market Insights for the Ovulation Inducing Drugs Industry?

The market size for ovulation-inducing drugs has seen robust growth in the past few years. This market is projected to expand from $4.42 billion in 2024 to $4.7 billion in 2025, with a compound annual growth rate (CAGR) of 6.5%. Factors contributing to this growth throughout the historic period include the creation of clomiphene citrate, the launch of letrozole, regulatory authorizations and standardizations, and the advent of ovulation predictor kits.

The market for ovulation inducing drugs is projected to experience significant expansion in the upcoming years, rising to “$6.11 billion in 2029 with a compound annual growth rate (CAGR) of 6.8%.” This projected growth during the forecast period is likely due to shifts in lifestyle and delayed child-rearing, integration of digital health, broader market accessibility, increased rates of infertility, and tailored treatment plans. Notable trends expected throughout the forecast period encompass individualized treatment strategies, progress in reproductive endocrinology, non-invasive methods for monitoring fertility, heightened demand for assisted reproductive technologies, and the advancement of new drug formulations.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13256&type=smp

What Forces Are Driving The Growth Of The Ovulation Inducing Drugs Industry?

The escalating instances of infertility among women is set to spur the expansion of the ovulation-inducing drug market. Women’s infertility is characterized by a woman’s inability to conceive or bring a pregnancy to full term, despite participating in frequent, unprotected sexual activity over a long term, often a year or longer. Ovulation-inducing drugs are utilized to remedy women’s infertility, specially addressing irregular or non-existent ovulation. These medicines act on the hormone pathways involved in ovulation, prompting the ovaries to eject mature eggs. According to the Centers for Disease Control and Prevention, a government agency in the US, by 2022, about 6.1 million women between 15 and 44 years old in the US may have difficulties getting pregnant, which accounts for 10% of all women. Moreover, as per CCRM Management Company LLC, a US-based medical management firm, in June 2022, infertility is expected to affect 1 out of every 4 couples worldwide, with an annual increment of 5% to 10%. As such, the growing instances of women’s infertility serve as a significant catalyst for the ovulation-inducing drug market’s growth.

The ovulation inducing drugs market covered in this report is segmented –

1) By Drug Class: Hormones, Therapeutics Drugs

2) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

3) By End-User: Hospital, Homecare, Specialty Clinics, Other End-Users

Subsegments:

1) By Hormones: Gonadotropins, Clomiphene Citrate, Aromatase Inhibitors

2) By Therapeutic Drugs: Metformin, Letrozole, Bromocriptine

What Future Market Trends Are Projected For The Ovulation Inducing Drugs Industry?

Leading businesses in the ovulation-inducing drugs market are making strides in the creation of inventive drugs like Cetrorelix acetate, which have been authorized for use in women experiencing controlled ovarian stimulation. Cetrorelix acetate for injection, more commonly known as cetrorelix, operates as an antagonist to the gonadotropin-releasing hormone (GnRH) and deters early ovulation in women who are going through in vitro fertilization (IVF). As an instance, Akorn Operating Company LLC, a pharmaceutical company located in the U.S., received FDA endorsement for a generic form of cetrorelix acetate for injection, 0.25 mg (Cetrorelix) in August 2022. This represents the early AP-rated bioequivalent version of Merck Serono Cetrotide that has received authorization. Cetrorelix acetate functions as a GnRH antagonist by counteracting the effects of the gonadotropin-releasing hormone (GnRH). GnRH instigates the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland. Its use extends to impeding premature LH bursts in women undergoing controlled ovarian stimulation (COS), aiding in ensuring the full maturation of all eggs.

Who Are The Primary Players Operating Across The Global Ovulation Inducing Drugs Market?

Major companies operating in the ovulation inducing drugs market report are Pfizer Inc., Johnson And Johnson Pvt Ltd., Merck And Co. Inc., Abbvie Inc., Novartis AG, Bayer AG, Sanofi SA, Abbott Laboratories, Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Janssen Pharmaceutical Inc., Mylan N.V, Astellas Pharma Inc., Sun Pharmaceuticals Industries Ltd., Aurobindo Pharma Limited, Dr Reddy’s Laboratories Ltd., Intas Pharmaceuticals Limited, Endo International Inc., Ferring Pharmaceuticals Inc., Lupin Limited, LIVZON Pharmaceutical Group Inc., Torrent Pharmaceuticals Ltd., Gedeon Richter PLC, Glenmark Pharmaceuticals Ltd., Fresenius Kabi AG, Zydus Pharmaceuticals (USA) Inc., Serum Institute of India Ltd., EMD Serono Inc., Cipla Inc.

https://www.thebusinessresearchcompany.com/report/ovulation-inducing-drugs-global-market-report

Which Region Offers The Most Growth Potential For The Ovulation Inducing Drugs Market Through 2029?

North America was the largest region in the ovulation-inducing drugs market in 2024. The regions covered in the ovulation inducing drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=13256&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model